Katerina Akassoglou Receives 2024 Pharmacia-ASPET Award

Katerina Akassoglou, PhD, FASPET

ASPET is pleased to award Dr. Katerina Akassoglou, PhD from the University of California, San Francisco, the 2024 Pharmacia-ASPET Award for Experimental Therapeutics. This award recognizes outstanding research in pharmacology and experimental therapeutics, basic laboratory or clinical research that has had, or potentially will have, a major impact on the pharmacological treatment of disease.

Dr. Akassoglou is receiving this award in recognition of her work on neurovascular and neuroimmune mechanisms that will have a major impact on the treatment of neurological diseases.

Dr. Katerina Akassoglou has pioneered studies on neurovascular regulation of inflammation and tissue repair and the molecular interface blood proteins utilize to interact with nervous system cells. She developed a first-in-class fibrin-targeting immunotherapy, currently in Phase 1, for the treatment of neurological diseases. She has published over 100 papers and is an inventor on 11 issued and several pending patents. She was awarded by the White House the Presidential Early Career Award for Scientists and Engineers, the John J. Abel Award in Pharmacology, the Dana Foundation and Marilyn Hilton Awards, the Barancik and ISFP Prizes and she was named by the San Francisco Business Times among the 2021 Most Influential Women in Bay Area Business. She is a Fellow of the American Neurological Association, an elected Fellow of the National Academy of Inventors, the American Association for the Advancement of Science and ASPET. She has been a member of ASPET since 2005.